Emerging natural killer cell immunotherapies: Large-scale ex vivo production of highly potent anticancer effectors

Caligiuri, 2008, Human natural killer cells, Blood, 112, 461, 10.1182/blood-2007-09-077438 Freud, 2006, Human natural killer cell development, Immunol Rev, 214, 56, 10.1111/j.1600-065X.2006.00451.x Natarajan, 2002, Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination, Annu Rev Immunol., 20, 853, 10.1146/annurev.immunol.20.100301.064812 Biassoni, 2003, Human natural killer cell receptors: insights into their molecular function and structure, J Cell Mol Med, 7, 376, 10.1111/j.1582-4934.2003.tb00240.x Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440 Velardi, 2002, NK cells: a lesson from mismatched hematopoietic transplantation, Trends Immunol, 23, 438, 10.1016/S1471-4906(02)02284-6 Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, 105, 3051, 10.1182/blood-2004-07-2974 Gill, 2009, Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses, Biol Blood Marrow Transplant, 15, 765, 10.1016/j.bbmt.2009.01.019 Fuchs, 2010, HLA-haploidentical stem cell transplantation for hematologic malignancies, Biol Blood Marrow Transplant, 16, S57, 10.1016/j.bbmt.2009.10.032 McKenna, 2007, Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience, Transfusion, 47, 520, 10.1111/j.1537-2995.2006.01145.x Lee, 2010, The role of natural killer cells in cancer therapy, Front Biosci (Elite Ed)., 2, 380, 10.2741/e98 Lowdell, 2000, Immunotherapy of AML: future directions, J Clin Pathol, 53, 49, 10.1136/jcp.53.1.49 Preti, 2001, Challenges associated with the development, manufacturing, and delivery of cellular medicines, Cancer J, 7, S62 Dietz, 2007, Infrastructure development for human cell therapy translation, Clin Pharmacol Ther, 82, 320, 10.1038/sj.clpt.6100288 Koh, 2008, Stem cell transplantation programme at Singapore General Hospital, Bone Marrow Transplant., 42, S121, 10.1038/bmt.2008.139 Gillis, 1978, T cell growth factor: parameters of production and a quantitative microassay for activity, J Immunol, 120, 2027, 10.4049/jimmunol.120.6.2027 Smith, 1988, Interleukin-2: inception, impact, and implications, Science, 240, 1169, 10.1126/science.3131876 Taniguchi, 1983, Structure and expression of a cloned cDNA for human interleu kin-2, Nature, 302, 305, 10.1038/302305a0 Fuchshuber, 1991, Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes, Lymphokine Cytokine Res, 10, 51 Sutlu, 2009, Natural killer cell-based immunotherapy in cancer: current insights and future prospects, J Intern Med, 266, 154, 10.1111/j.1365-2796.2009.02121.x Henney, 1981, Interleukin-2 augments natural killer cell activity, Nature, 291, 335, 10.1038/291335a0 Lotzova, 1987, Induction of NK cell activity against fresh human leukemia in culture with interleukin 2, J Immunol, 138, 2718, 10.4049/jimmunol.138.8.2718 Lotzova, 1987, Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors, Leuk Res, 11, 1059, 10.1016/0145-2126(87)90158-5 Rosenberg, 1985, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant inter-leukin-2 to patients with metastatic cancer, N Engl J Med, 313, 1485, 10.1056/NEJM198512053132327 Rosenberg, 1989, Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Ann Surg, 210, 474, 10.1097/00000658-198910000-00008 Bordignon, 1999, Cell therapy: achievements and perspectives, Haematologica, 84, 1110 Suck, 2006, Novel approaches using natural killer cells in cancer therapy, Semin Cancer Biol, 16, 412, 10.1016/j.semcancer.2006.07.006 Margolin, 2000, Interleukin-2 in the treatment of renal cancer, Semin Oncol, 27, 194 Rosenberg, 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and inter-leukin-2 or high-dose interleukin-2 alone, N Engl J Med, 316, 889, 10.1056/NEJM198704093161501 Phan, 2001, Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma, J Clin Oncol, 19, 3477, 10.1200/JCO.2001.19.15.3477 Arina, 2007, Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer, Expert Opin Biol Ther, 7, 599, 10.1517/14712598.7.5.599 Soiffer, 1996, Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2, Clin Cancer Res, 2, 493 Meropol, 1998, Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing, Cancer Immunol Immunother, 46, 318, 10.1007/s002620050493 Fehniger, 2002, Interleukin-2 and interleukin-15: immunotherapy for cancer, Cytokine Growth Factor Rev, 13, 169, 10.1016/S1359-6101(01)00021-1 Burns, 2003, IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial, Bone Marrow Transplant, 32, 177, 10.1038/sj.bmt.1704086 Buzio, 2001, Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma, Cancer, 92, 2286, 10.1002/1097-0142(20011101)92:9<2286::AID-CNCR1575>3.0.CO;2-I Miller, 2009, Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential?, Cytotherapy, 11, 259, 10.1080/14653240902888000 Ruggeri, 2008, NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation, Blood Cells Mol Dis, 40, 84, 10.1016/j.bcmd.2007.06.029 Moretta, 2010, Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias, Tissue Antigens, 75, 103, 10.1111/j.1399-0039.2009.01404.x Petersen, 2007, Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning, Dan Med Bull., 54, 112 Rubnitz, 2010, NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia, J Clin Oncol, 28, 955, 10.1200/JCO.2009.24.4590 Verneris, 2010, Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time?, J Clin Oncol, 28, 909, 10.1200/JCO.2009.26.4002 Wall, 2003, Regulation of cellular therapies: the Australian perspective, Cytotherapy, 5, 284, 10.1080/14653240310002207 Warkentin, 2003, Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT), Cytotherapy, 5, 299, 10.1080/14653240310002298 Caunday, 2009, Regulatory aspects of cellular therapy product in Europe: JACIE accreditation in a processing facility, Biomed Mater Eng, 19, 373 Linn, 2010, Cytokine-induced NK-like T cells: from bench to bedside, J Biomed Biotechnol., 2010, 435745, 10.1155/2010/435745 Fuchshuber, 1991, Feeder cells enhance oncolytic and proliferative activity of long-term human bone marrow interleukin-2 cultures and induce different lymphocyte subsets, Cancer Immunol Immunother, 33, 15, 10.1007/BF01742522 Perussia, 1987, Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lympho-blastoid cell lines, Nat Immun Cell Growth Regul, 6, 171 Rabinowich, 1991, Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells, Cell Immunol, 135, 454, 10.1016/0008-8749(91)90290-R Miller, 1994, Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy, Bone Marrow Transplant, 14, 555 Torelli, 2002, Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission, Br J Haematol, 116, 299, 10.1046/j.1365-2141.2002.03277.x Barkholt, 2009, Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study, Immunotherapy, 1, 753, 10.2217/imt.09.47 Berg, 2009, Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells, Cytotherapy, 11, 341, 10.1080/14653240902807034 Fujisaki, 2009, Expansion of highly cytotoxic human natural killer cells for cancer cell therapy, Cancer Res, 69, 4010, 10.1158/0008-5472.CAN-08-3712 Meehan, 2008, Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy, Cytotherapy, 10, 30, 10.1080/14653240701762398 Cho, 2009, Expansion and activation of natural killer cells for cancer immunotherapy, Korean J Lab Med, 29, 89, 10.3343/kjlm.2009.29.2.89 Klingemann, 2004, Ex vivo expansion of natural killer cells for clinical applications, Cytotherapy, 6, 15, 10.1080/14653240310004548 Carlens, 2001, A new method for in vitroexpansion of cytotoxic human CD3-CD56+ natural killer cells, Hum Immunol, 62, 1092, 10.1016/S0198-8859(01)00313-5 Alici, 2008, Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components, Blood, 111, 3155, 10.1182/blood-2007-09-110312 Guven, 2003, Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy, Leukemia, 17, 1973, 10.1038/sj.leu.2403083 Fujisaki, 2009, Replicative potential of human natural killer cells, Br J Haematol, 145, 606, 10.1111/j.1365-2141.2009.07667.x Cho, 2010, Cytotoxicity of Activated Natural Killer Cells Against Pediatric Solid Tumors, Clin Cancer Res, 10.1158/1078-0432.CCR-10-0735 Li, 2010, Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method, Cancer Gene Ther, 17, 147, 10.1038/cgt.2009.61 Romanski, 2005, Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia, Exp Hematol, 33, 344, 10.1016/j.exphem.2004.11.006 Siegler, 2010, Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients, Cytotherapy, 10.3109/14653241003786155 Langenkamp, 2009, Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells, Haematologica, 94, 1590, 10.3324/haematol.2009.005967 Lundqvist, 2006, Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity, Cancer Res, 66, 7317, 10.1158/0008-5472.CAN-06-0680 Shen, 2007, Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitroand in vivo pre-clinical evaluation, Blood, 110, 469, 10.1182/blood-2007-02-072900 Reddy, 2010, Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies, Ann Oncol, 10.1093/annonc/mdq009 Einsele, 2010, Bortezomib. Recent Results Cancer Res., 184, 173, 10.1007/978-3-642-01222-8_12 Armeanu, 2008, Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma, Clin Cancer Res, 14, 3520, 10.1158/1078-0432.CCR-07-4744 Hallett, 2008, Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition, J Immunol, 180, 163, 10.4049/jimmunol.180.1.163 Shi, 2008, Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma, Blood, 111, 1309, 10.1182/blood-2007-03-078535 Markasz, 2007, Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells, Mol Cancer Ther, 6, 644, 10.1158/1535-7163.MCT-06-0358 Feng, 2010, The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells, Mol Immunol, 10.1016/j.molimm.2010.05.003 Lin, 2008, Combined immunogene therapy of IL-6 and IL-15 enhances antitumor activity through augmented NK cytotoxicity, Cancer Lett, 272, 285, 10.1016/j.canlet.2008.07.016 Yoon, 2009, Generation of donor natural killer cells from CD34 (+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study, Bone Marrow Transplant, 45, 1038, 10.1038/bmt.2009.304 Decot, 2010, Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression, Exp Hematol, 38, 351, 10.1016/j.exphem.2010.02.006 Rutella, 2003, Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitroexposure to IL-15, J Immunol, 171, 2977, 10.4049/jimmunol.171.6.2977 Kao, 2007, Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34+ cells, Stem Cells Dev, 16, 1043, 10.1089/scd.2007.0033 Spanholtz, 2010, High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy, PLoS One, 5, e9221, 10.1371/journal.pone.0009221 Verneris, 2009, The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells, Br J Haematol, 147, 185, 10.1111/j.1365-2141.2009.07768.x Leung, 2004, Determinants of antileukemia effects of allogeneic NK cells, J Immunol, 172, 644, 10.4049/jimmunol.172.1.644 Szczepanski, 2009, Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors, Cancer Immunol Immunother Tonn, 2001, Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92, J Hematother Stem Cell Res, 10, 535, 10.1089/15258160152509145